How should malignant hyperthermia be managed in postoperative patients with a ventriculostomy?

Management of Malignant Hyperthermia in Postoperative Patients with Ventriculostomy

Manage malignant hyperthermia in postoperative patients with ventriculostomy using the same aggressive treatment protocol as any MH crisis: immediately administer intravenous dantrolene 2-3 mg/kg, hyperventilate with 100% oxygen, and initiate active cooling—the presence of a ventriculostomy does not contraindicate standard MH treatment and may actually facilitate temperature monitoring.

Immediate Treatment Protocol

The cornerstone of MH management remains dantrolene administration regardless of concurrent neurosurgical interventions 1. The treatment algorithm follows these steps:

Dantrolene Administration

• Give dantrolene 2-3 mg/kg IV immediately upon suspicion of MH 1
• Repeat 1 mg/kg every 5 minutes until end-tidal CO₂ is <6 kPa with normal minute ventilation and core temperature is <38.5°C 1
• The maximum dose of 10 mg/kg may need to be exceeded 1
• Each 20 mg ampoule requires mixing with 60 ml sterile water; obtain at least 36-50 ampoules for an adult patient 1

Respiratory Management

• Hyperventilate with 2-3 times normal minute volume using 100% oxygen at high flow 1
• Continue hyperventilation to achieve normocapnoea 1
• Monitor end-tidal CO₂ continuously as an early indicator of treatment response 1

Temperature Control

• Administer 2000-3000 ml of chilled (4°C) 0.9% saline intravenously 1
• Apply surface cooling with wet, cold sheets, fans, and ice packs in axillae and groin 1
• Stop cooling once temperature drops below 38.5°C 1
• The ventriculostomy provides an advantage for accurate core temperature monitoring 1

Metabolic Derangement Management

Hyperkalaemia Treatment

• Administer dextrose 50%, 50 ml with 50 IU insulin (adult dose) 1
• Give calcium chloride 0.1 mmol/kg IV (e.g., 7 mmol = 10 ml for 70 kg adult) 1
• Dialysis may be required in severe cases 1

Acidosis Correction

• Hyperventilate to normocapnoea as first-line treatment 1
• Administer sodium bicarbonate IV if pH <7.2 1

Arrhythmia Management

• Use amiodarone 300 mg for adults (3 mg/kg IV) 1
• Consider beta-blockers (propranolol/metoprolol/esmolol) if tachycardia persists 1

Monitoring Requirements

Essential Monitoring

• Continue routine anaesthetic monitoring (SpO₂, ECG, non-invasive blood pressure, end-tidal CO₂) 1
• Measure core temperature continuously—the ventriculostomy catheter can serve this purpose 1
• Establish wide-bore IV cannulas for rapid fluid and medication administration 1
• Consider arterial and central venous line insertion 1
• Insert urinary catheter if not already present 1

Laboratory Monitoring

• Obtain samples for K⁺, creatine kinase, arterial blood gases, myoglobin, and glucose 1
• Check renal and hepatic function and coagulation parameters 1
• Monitor for signs of compartment syndrome 1
• Monitor the patient for a minimum of 24 hours in ICU, HDU, or recovery unit 1

Renal Protection

Maintain urinary output >2 ml/kg/h using 1:

• Furosemide 0.5-1 mg/kg
• Mannitol 1 g/kg
• Crystalloid fluids (lactated Ringer's solution or 0.9% saline) IV

Postoperative MH Considerations

Timing and Presentation

• Postoperative MH is uncommon (1.9% of reported MH cases) but can occur 2
• The latency period between anesthesia completion and MH onset ranges from 0-40 minutes 2
• Hyperthermia is never the presenting sign of postoperative MH—look for generalized rigidity, hypercapnia/tachypnea, and tachycardia first 2
• All postoperative MH cases in the registry received volatile agents, with half also receiving succinylcholine 2

Neurosurgical Context

• Cardiac surgery cases demonstrate that cardiopulmonary bypass can obscure MH signs, suggesting that neurosurgical procedures may similarly complicate diagnosis 3, 4
• Delayed recognition in the postoperative period can cause permanent neurologic damage or death 4
• Maintain high index of suspicion in any postoperative patient with unexplained fever, acidosis, and muscle rigidity following volatile anesthetic exposure 4

Critical Pitfalls to Avoid

Do not delay dantrolene administration while attempting to differentiate MH from other causes of postoperative fever—early treatment is essential for survival 1. The presence of a ventriculostomy should not alter your treatment approach, as there are no contraindications to standard MH therapy in neurosurgical patients 1.

Do not assume the patient is safe simply because they tolerated previous anesthetics—MH can occur even in patients with uneventful prior general anesthesia 1.

Do not stop treatment prematurely—continue dantrolene infusions until cardiac and respiratory systems stabilize, which may require exceeding the traditional maximum dose 1.

Follow-up Requirements

After stabilization, consult your local Malignant Hyperthermia Investigation Unit about the case 1. Patients suspected of being MH-susceptible should undergo diagnostic testing using in vitro contracture testing (IVCT) at a designated MH laboratory, and the patient and their relatives should be referred to a regional or national MH center for further investigation 1.